Robert Kralovics

Center for Molecular Medicine, Austrian Academy of Sciences, Austria
Professor

Scopus Profile: link
Profile Google Scholar: link
ID ORCID: http://orcid.org/0000-0002-6997-8539

Professional (scientific) interests: Hematopoietic malignancies (genetics and therapy); Cancer genetics

Selected Publications:

  1. Borsani, O., Jäger, R., Pietra, D., Flieder, I., Riccaboni, G., Kralovics, R., Rumi, E. (2024). Evaluation of the & ATM L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms. Haematologica. https://doi.org/10.3324/haematol.2024.285539

  2. Jäger, R., Hoke, M., Mayer, F. J., Boden, S., Englisch, C., Ay, C., Kralovics, R., Binder, C. J. (2024). Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality. Journal of the American College of Cardiology, 83 (18), 1717–1727. https://doi.org/10.1016/j.jacc.2024.02.043

  3. Jäger, R., Geyer, S. H., Kavirayani, A., Kiss, M. G., Waltenberger, E., Rülicke, T., Binder, C. J., Weninger, W. J., Kralovics, R. (2023). Effects of Tulp4 deficiency on murine embryonic development and adult phenotype. Microscopy Research and Technique, 87 (4), 854–866. https://doi.org/10.1002/jemt.24476

  4. Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Empson, V., Hasselbalch, H. C., Kralovics, R., Kiladjian, J.-J., Gisslinger, H., Kiladjian, J.-J. (2023). Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia, 37 (10), 2129–2132. https://doi.org/10.1038/s41375-023-02008-6

  5. Kralovics, R., Ivanov, D., Milosevic Feenstra, J. D., Sadovnik, I., Herrmann, H., Peter, B., Willmann, M., Greiner, G., Slavnitsch, K., Hadzijusufovic, E., Rülicke, T., Dahlhoff, M., Hoermann, G., Machherndl‐Spandl, S., Eisenwort, G., Fillitz, M., Sliwa, T., Krauth, M., Bettelheim, P., Sperr, W. RValent, P. et al. (2023). Phenotypic characterization of disease‐initiating stem cells in JAK2 or CALR‐mutated myeloproliferative neoplasms. American Journal of Hematology, 98 (5), 770–783. https://doi.org/10.1002/ajh.26889

  6. Luque Paz, D., Kralovics, R., Skoda, R. C. (2022). Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood, 141 (16), 1909–1921. https://doi.org/10.1182/blood.2022017578

  7. Pecquet, C., Papadopoulos, N., Balligand, T., Chachoua, I., Tisserand, A., Vertenoeil, G., Nédélec, A., Vertommen, D., Roy, A., Marty, C., Nivarthi, H., Defour, J.-P., El-Khoury, M., Hug, E., Majoros, A., Xu, E., Zagrijtschuk, O., Fertig, T. E., Marta, D. S., Constantinescu, S. N. et al. (2023). Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms. Blood, 141 (8), 917–929. https://doi.org/10.1182/blood.2022016846